Avalo Therapeutics, INC Schedule 13G passive stakes

RA Capital Management and its affiliates report a 9.9% beneficial ownership stake in Avalo Therapeutics, Inc. as of September 30, 2025.

Point72 Asset Management, along with affiliates and Steven A. Cohen, reported an 8.0% beneficial ownership in Avalo Therapeutics, Inc. common stock.

Biotechnology Value Fund and its affiliates, including Mark N. Lampert, reported a combined beneficial ownership of 9.99% in Avalo Therapeutics, Inc. common stock as of September 30, 2025.

Caligan Partners LP and David Johnson have reported a passive 6.3% ownership stake in Avalo Therapeutics, Inc., holding 833,333 shares of common stock.

SilverArc Capital Management and Devesh Gandhi have reported a 5.48% beneficial ownership stake in Avalo Therapeutics, Inc.'s Class A Common Stock.

Deep Track Capital and its affiliates have fully divested their holdings in Avalo Therapeutics, Inc., now owning 0% of the common stock.

Balyasny Asset Management and its affiliates have reported a 6.22% beneficial ownership stake in Avalo Therapeutics Inc., totaling 817,436 shares.

Affinity Healthcare Fund and Affinity Asset Advisors disclose a 7.65% beneficial ownership in Avalo Therapeutics, which has since decreased to 6.01% due to share dilution.

The Vanguard Group has reported a passive 5.26% beneficial ownership stake in Avalo Therapeutics Inc. common stock.

Patrick J. Crutcher has reported a 4.2% beneficial ownership stake in Avalo Therapeutics, Inc., holding 549,467 shares of common stock.

OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC filed an amended Schedule 13G, updating their beneficial ownership in Avalo Therapeutics, Inc.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, disclosed a 5.4% beneficial ownership stake in Avalo Therapeutics, Inc.

Investment firm Ikarian Capital, LLC and its sole manager Neil Shahrestani have disclosed a 9.99% beneficial ownership stake in Avalo Therapeutics, Inc., primarily through common stock and convertible preferred stock.

RA Capital Management and its affiliates have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.9% in Avalo Therapeutics, Inc., limited by a beneficial ownership blocker on convertible preferred stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 8.43% in Avalo Therapeutics, Inc. as of March 31, 2025.

Affiliates of Biotechnology Value Fund (BVF) have filed an amended Schedule 13G, revealing a collective beneficial ownership of 9.99% of Avalo Therapeutics, Inc.'s common stock as of December 31, 2024.